|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000185950 |
Summary for IRS2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000185950 | Gene symbol | IRS2 |
| Gene name | insulin receptor substrate 2 | |
| HGNC | 6126 | |
| Entrez ID | 8660 | |
| Gene type | protein_coding | |
| Synonyms | IRS2| | |
| UniProtAcc | Q9Y4H2 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for IRS2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| IRS2 | 2.69e+03 | -1.46e+00 | 1.23e-01 | -1.19e+01 | 1.97e-32 | 1.10e-31 | BRCA |
| IRS2 | 2.88e+03 | 1.11e+00 | 3.50e-01 | 3.18e+00 | 1.46e-03 | 4.81e-03 | READ |
Top |
Sex-biased somatic mutation for IRS2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for IRS2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg10488031 | chr13:109785214 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 4.95e-01 | 3.88e-01 | 2.07e+00 | 3.84e-02 | 4.52e-02 | 1.07e-01 |
| SARC | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 3.56e-01 | 2.18e-01 | 3.34e+00 | 8.46e-04 | 3.06e-03 | 1.38e-01 |
| ESCA | cg05404236 | chr13:109784746 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 5.21e-01 | 3.63e-01 | 2.90e+00 | 3.78e-03 | 1.36e-02 | 1.59e-01 |
| THYM | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 3.49e-01 | 2.29e-01 | 6.42e+00 | 1.41e-10 | 6.38e-10 | 1.20e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BLCA | cg05404236 | chr13:109784746 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 5.10e-01 | 2.56e-01 | 2.69e+00 | 7.19e-03 | 1.09e-02 | 2.54e-01 |
| BLCA | cg16851425 | chr13:109785412 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 2.70e-01 | 1.10e-01 | 2.59e+00 | 9.67e-03 | 1.38e-02 | 1.60e-01 |
| LIHC | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 1.97e-01 | 3.03e-01 | 2.26e+00 | 2.41e-02 | 2.64e-02 | -1.05e-01 |
| KIRP | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 3.27e-01 | 1.98e-01 | 3.56e+00 | 3.69e-04 | 7.84e-04 | 1.29e-01 |
| CHOL | cg10488031 | chr13:109785214 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 3.16e-01 | 4.37e-01 | -2.29e+00 | 2.23e-02 | 3.24e-02 | -1.21e-01 |
| CHOL | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 1.55e-01 | 3.22e-01 | -3.02e+00 | 2.51e-03 | 1.19e-02 | -1.67e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg10488031 | chr13:109785214 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 5.02e-01 | 4.02e-01 | 2.38e+00 | 1.75e-02 | 2.46e-02 | 1.00e-01 |
| KIRC | cg06293108 | chr13:109785909 | CGI:chr13:109782266-109787833 | promoter,exon,CDS,gene body | 2.05e-01 | 1.02e-01 | 3.30e+00 | 9.83e-04 | 4.47e-03 | 1.03e-01 |
| HNSC | cg06549607 | chr13:109788005 | CGI:chr13:109782266-109787833 | promoter | 2.45e-01 | 1.33e-01 | 2.56e+00 | 1.06e-02 | 1.92e-02 | 1.12e-01 |
Top |
Exon skipping events with PSI in TCGA for IRS2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for IRS2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for IRS2 |
| TFs related to IRS2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SARC | PATZ1 | IRS2 | 3.73e+00 | 1.10e-02 | 4.35e+00 | 9.81e-01 | Female-biased |
| SARC | ZNF141 | IRS2 | 3.71e+00 | 7.50e-03 | 4.40e+00 | 9.85e-01 | Female-biased |
| SARC | ZNF28 | IRS2 | 3.66e+00 | 5.09e-03 | 4.42e+00 | 9.88e-01 | Female-biased |
| SARC | ZNF460 | IRS2 | 4.01e+00 | 1.41e-02 | 4.60e+00 | 9.81e-01 | Female-biased |
| SARC | ZNF816 | IRS2 | 3.66e+00 | 1.02e-02 | 4.30e+00 | 9.81e-01 | Female-biased |
| IRS2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for IRS2 |
| RBPs related to ES in IRS2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| IRS2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9515455 | chr13:111587324:G:A | - | 0.137098861750331 | 0.04652135302356 | READ | Female-baised eQTL |
| rs9585619 | chr13:101078456:C:T | - | 0.116329249647112 | 0.0400851948565921 | SARC | Female-baised eQTL |
| rs725122 | chr13:108406051:G:A | - | 0.188789740254216 | 0.0159949078736601 | KIRP | Female-baised eQTL |
| rs16970167 | chr13:107469328:G:A | - | 0.243401949353024 | 0.0178602394642552 | KIRP | Female-baised eQTL |
| rs12585674 | chr13:100763240:G:C | - | 0.148188130029369 | 0.00148412431898331 | STAD | Female-baised eQTL |
| rs2063910 | chr13:100763427:A:G | - | 0.148188130029369 | 0.00148412431898331 | STAD | Female-baised eQTL |
| rs72647011 | chr13:100771838:A:G | - | 0.151552583220585 | 0.00219072799792468 | STAD | Female-baised eQTL |
| rs72663042 | chr13:100759971:G:A | - | 0.151134218234913 | 0.00233295028271842 | STAD | Female-baised eQTL |
| rs34062441 | chr13:112219452:G:T | - | 0.106342305712183 | 0.0119997770737247 | STAD | Female-baised eQTL |
| rs9583333 | chr13:109033373:G:A | - | 0.157499128511973 | 0.0166048629185656 | STAD | Female-baised eQTL |
| rs9583334 | chr13:109033452:C:T | - | 0.157499128511973 | 0.0166048629185656 | STAD | Female-baised eQTL |
| rs9521136 | chr13:109033869:A:T | - | 0.15701276865847 | 0.0175908760451072 | STAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9559429 | chr13:108868790:A:G | - | 0.074453460833129 | 0.0313238829337319 | HNSC | Male-baised eQTL |
| rs9559428 | chr13:108866230:T:C | - | 0.0720257286355577 | 0.0341031464844712 | HNSC | Male-baised eQTL |
| rs61971380 | chr13:108867126:T:C | - | 0.0727869495302947 | 0.0413112172001709 | HNSC | Male-baised eQTL |
| rs61971377 | chr13:108858957:A:T | - | 0.0732803626943609 | 0.0496517543841122 | HNSC | Male-baised eQTL |
| rs958378 | chr13:111092591:A:C | - | -0.106376331966582 | 0.0119027265989646 | THCA | Male-baised eQTL |
| rs4238283 | chr13:111082863:A:C | - | -0.100785434446271 | 0.0165005271712949 | THCA | Male-baised eQTL |
| rs9515374 | chr13:111085248:C:T | - | -0.104513061260338 | 0.0171204336585025 | THCA | Male-baised eQTL |
| rs9515369 | chr13:111082436:G:A | - | -0.0962576971525119 | 0.0348243580155505 | THCA | Male-baised eQTL |
| rs7317390 | chr13:110332630:C:T | - | -0.0968544123745467 | 0.00217234046525772 | LIHC | Male-baised eQTL |
| rs17621742 | chr13:101162606:G:A | - | 0.0675819242808792 | 5.20684778951454e-05 | LGG | Male-baised eQTL |
| rs9518759 | chr13:102521985:G:A | - | 0.0653035197888301 | 0.000260803785986967 | LGG | Male-baised eQTL |
| rs4772483 | chr13:102512515:C:T | - | 0.0652973101222532 | 0.000264152904150762 | LGG | Male-baised eQTL |
| rs9518763 | chr13:102529183:G:A | - | 0.0645159622345015 | 0.000364209086533321 | LGG | Male-baised eQTL |
| rs17678261 | chr13:101162691:A:C | - | 0.0604755803451395 | 0.000386581127362616 | LGG | Male-baised eQTL |
| rs4771387 | chr13:101163155:G:A | - | 0.0604755803451395 | 0.000386581127362616 | LGG | Male-baised eQTL |
| rs113000843 | chr13:102531551:C:G | - | 0.0643286626493577 | 0.000394781143380487 | LGG | Male-baised eQTL |
| rs10508088 | chr13:102489224:G:A | - | 0.0596121232564569 | 0.00051237783898146 | LGG | Male-baised eQTL |
| rs11618953 | chr13:101161426:C:T | - | 0.0591636083842599 | 0.000528197685854524 | LGG | Male-baised eQTL |
| rs3015384 | chr13:105158795:T:C | - | 0.0627301186254327 | 0.000532126903714127 | LGG | Male-baised eQTL |
| rs72652920 | chr13:101181486:C:G | - | 0.0564621167573819 | 0.000692923265300741 | LGG | Male-baised eQTL |
| rs55814435 | chr13:101172703:G:C | - | 0.0588100181590622 | 0.000825757028421861 | LGG | Male-baised eQTL |
| rs59229434 | chr13:101188065:T:A | - | 0.0525632844928125 | 0.00123028871385259 | LGG | Male-baised eQTL |
| rs59088048 | chr13:101188119:T:G | - | 0.0525632844928125 | 0.00123028871385259 | LGG | Male-baised eQTL |
| rs16958539 | chr13:101186784:A:G | - | 0.0495219133577004 | 0.00147647170925643 | LGG | Male-baised eQTL |
| rs5021665 | chr13:105135069:A:G | - | -0.0638971029538236 | 0.00147701721072217 | LGG | Male-baised eQTL |
| rs7982111 | chr13:101187902:C:T | - | 0.0517179007338321 | 0.00150200749157345 | LGG | Male-baised eQTL |
| rs61456777 | chr13:101188159:T:C | - | 0.0525754591486855 | 0.00252976827612227 | LGG | Male-baised eQTL |
| rs17621925 | chr13:101186732:C:T | - | 0.0493301854113486 | 0.00298915874271397 | LGG | Male-baised eQTL |
| rs72652930 | chr13:101188056:C:G | - | 0.0534033570197452 | 0.00312197483535827 | LGG | Male-baised eQTL |
| rs7981101 | chr13:101187469:A:C | - | 0.0481360563362807 | 0.00367748486964541 | LGG | Male-baised eQTL |
| rs34866160 | chr13:103583788:A:G | - | 0.0586528073517191 | 0.00731885130748559 | LGG | Male-baised eQTL |
| rs147885127 | chr13:110084255:G:A | - | 0.0499637677880163 | 0.00892535876705394 | LGG | Male-baised eQTL |
| rs4349008 | chr13:105150705:G:A | - | 0.0445496813337211 | 0.0172350859360439 | LGG | Male-baised eQTL |
| rs3015374 | chr13:105143381:A:C | - | 0.0439982553324103 | 0.0186755330744159 | LGG | Male-baised eQTL |
| rs3007270 | chr13:105143473:A:G | - | 0.0439982553324103 | 0.0186755330744159 | LGG | Male-baised eQTL |
| rs3015375 | chr13:105143780:G:A | - | 0.0439982553324103 | 0.0186755330744159 | LGG | Male-baised eQTL |
| rs3015379 | chr13:105144838:T:C | - | 0.0436360331586988 | 0.0211738761090788 | LGG | Male-baised eQTL |
| rs3015376 | chr13:105144098:G:A | - | 0.0426899944389531 | 0.0262368243720476 | LGG | Male-baised eQTL |
| rs3015377 | chr13:105144112:G:C | - | 0.0426899944389531 | 0.0262368243720476 | LGG | Male-baised eQTL |
| rs3015378 | chr13:105144115:G:A | - | 0.0426899944389531 | 0.0262368243720476 | LGG | Male-baised eQTL |
| rs812382 | chr13:105525716:C:T | - | 0.0356857596758817 | 0.0352120430278417 | LGG | Male-baised eQTL |
| rs12585133 | chr13:103593692:C:T | - | 0.041970349409694 | 0.0433017448651947 | LGG | Male-baised eQTL |
| rs7323147 | chr13:108465178:A:G | - | 0.0342437919024341 | 0.0461735396317613 | LGG | Male-baised eQTL |
| rs3015369 | chr13:105140959:G:C | - | 0.0397603229252132 | 0.047034764523166 | LGG | Male-baised eQTL |
| rs3015371 | chr13:105142057:T:C | - | 0.0396481419044948 | 0.0482178299484006 | LGG | Male-baised eQTL |
| rs3007259 | chr13:105142252:T:A | - | 0.0396481419044948 | 0.0482178299484006 | LGG | Male-baised eQTL |
| rs3007261 | chr13:105142604:A:T | - | 0.0396481419044948 | 0.0482178299484006 | LGG | Male-baised eQTL |
| rs3007263 | chr13:105142873:C:T | - | 0.0396481419044948 | 0.0482178299484006 | LGG | Male-baised eQTL |
| rs3015373 | chr13:105143236:G:A | - | 0.0396481419044948 | 0.0482178299484006 | LGG | Male-baised eQTL |
| rs3015372 | chr13:105142243:G:A | - | 0.039912136852742 | 0.0490432397250014 | LGG | Male-baised eQTL |
| rs9518553 | chr13:101796346:T:C | - | -0.0496362139609523 | 0.0171624878202151 | KIRC | Male-baised eQTL |
| rs913462 | chr13:101795744:A:G | - | -0.0489171468055172 | 0.017902623952843 | KIRC | Male-baised eQTL |
| rs7319685 | chr13:101800918:C:G | - | -0.049943177208883 | 0.0188788404858108 | KIRC | Male-baised eQTL |
| rs1407580 | chr13:101795589:A:G | - | -0.0492258067852129 | 0.0212852734750412 | KIRC | Male-baised eQTL |
| rs12428110 | chr13:101794509:C:A | - | -0.0490241988002458 | 0.0228910702940705 | KIRC | Male-baised eQTL |
| rs3918325 | chr13:101794745:T:C | - | -0.0485913372131127 | 0.0247884772646747 | KIRC | Male-baised eQTL |
| rs9518546 | chr13:101787707:A:G | - | -0.0478712581606856 | 0.0347070377029315 | KIRC | Male-baised eQTL |
| rs9513952 | chr13:101781643:T:G | - | -0.0469223811411683 | 0.0464285531562302 | KIRC | Male-baised eQTL |
| rs10508075 | chr13:101786833:A:G | - | -0.0463085523096437 | 0.0466365011632235 | KIRC | Male-baised eQTL |
| rs56218452 | chr13:108380954:T:C | - | 0.0941731371888459 | 0.0011331848908965 | BLCA | Male-baised eQTL |
| rs9583233 | chr13:108353002:T:A | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs74115373 | chr13:108354085:A:G | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9587558 | chr13:108354754:C:T | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9301292 | chr13:108358525:T:C | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9587559 | chr13:108360986:A:G | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9583234 | chr13:108362115:G:T | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9587560 | chr13:108364917:A:C | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9587561 | chr13:108365514:C:A | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs9583235 | chr13:108375578:T:C | - | 0.0941065281676564 | 0.00115717064506907 | BLCA | Male-baised eQTL |
| rs73588154 | chr13:103328376:A:G | - | 0.090353717191455 | 0.00679714570947944 | BLCA | Male-baised eQTL |
| rs9519494 | chr13:104844451:A:G | - | -0.0529233914051565 | 0.00982058732600325 | BLCA | Male-baised eQTL |
| rs35651638 | chr13:103014620:C:A | - | 0.103778663538268 | 0.0098384406257576 | BLCA | Male-baised eQTL |
| rs73576222 | chr13:103319911:C:T | - | 0.0835619883508568 | 0.0152037021723916 | BLCA | Male-baised eQTL |
| rs9585564 | chr13:100948553:G:A | - | 0.0525976556698777 | 0.0154474573202297 | BLCA | Male-baised eQTL |
| rs56320337 | chr13:100939928:C:A | - | 0.0508333502724907 | 0.0154947402586721 | BLCA | Male-baised eQTL |
| rs1819367 | chr13:109236725:C:T | - | 0.108047593213953 | 0.0157783174917123 | BLCA | Male-baised eQTL |
| rs9583349 | chr13:109238117:C:A | - | 0.108047593213953 | 0.0157783174917123 | BLCA | Male-baised eQTL |
| rs932723 | chr13:109238461:T:C | - | 0.108047593213953 | 0.0157783174917123 | BLCA | Male-baised eQTL |
| rs7990153 | chr13:100928265:T:C | - | 0.0494871564398179 | 0.0174438862753824 | BLCA | Male-baised eQTL |
| rs76366871 | chr13:100357317:C:T | - | 0.0871182102960032 | 0.0176437888164772 | BLCA | Male-baised eQTL |
| rs73574246 | chr13:103317170:C:A | - | 0.0811812284464754 | 0.0199928649550247 | BLCA | Male-baised eQTL |
| rs72649124 | chr13:100925844:G:A | - | 0.0495201645021265 | 0.0209954607188338 | BLCA | Male-baised eQTL |
| rs11620055 | chr13:109151729:T:G | - | 0.0930608327433067 | 0.0222886953219248 | BLCA | Male-baised eQTL |
| rs12431137 | chr13:103331921:G:T | - | 0.0803187124099524 | 0.0230258770634988 | BLCA | Male-baised eQTL |
| rs12427879 | chr13:103330391:T:G | - | 0.0791486355230459 | 0.0256329431221708 | BLCA | Male-baised eQTL |
| rs61969403 | chr13:109209707:C:T | - | 0.0969385237861876 | 0.0280612116352915 | BLCA | Male-baised eQTL |
| rs9519613 | chr13:105103883:A:G | - | -0.0570195084058007 | 0.0341768149871286 | BLCA | Male-baised eQTL |
| rs9514367 | chr13:105097441:T:C | - | -0.0572526506117591 | 0.0342167813141012 | BLCA | Male-baised eQTL |
| rs7994412 | chr13:105097515:T:G | - | -0.0572526506117591 | 0.0342167813141012 | BLCA | Male-baised eQTL |
| rs34385703 | chr13:102986184:A:T | - | 0.0914943233750149 | 0.0348296456727257 | BLCA | Male-baised eQTL |
| rs7999626 | chr13:103331367:A:G | - | 0.0748689068936345 | 0.0401954183957956 | BLCA | Male-baised eQTL |
| rs34836691 | chr13:103014574:G:A | - | 0.0882482996897642 | 0.0409176862104971 | BLCA | Male-baised eQTL |
| rs7328206 | chr13:105102921:A:G | - | -0.0554682836600198 | 0.0438849198898248 | BLCA | Male-baised eQTL |
| rs7327955 | chr13:105102548:G:A | - | -0.0554921027867897 | 0.0439054605322586 | BLCA | Male-baised eQTL |
| rs9514366 | chr13:105097190:C:G | - | -0.0552340111471139 | 0.0465734573940487 | BLCA | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg01569664 | |
| Position to Gene: gene | |
| Male Effect: -0.333596042670849 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg12085119 | |
| Position to Gene: gene | |
| Male Effect: -0.288196190398417 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg20445402 | |
| Position to Gene: gene | |
| Male Effect: -0.470330372596656 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg25924746 | |
| Position to Gene: gene | |
| Male Effect: -0.275993907045403 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg20445402 | |
| Position to Gene: gene | |
| Male Effect: -0.255209984176809 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg21266798 | |
| Position to Gene: gene | |
| Male Effect: -0.459205639333708 | |
| Female Effect: - | |
 | Gene ID: ENSG00000185950 |
| CpG Site: cg10488031 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.453634638511449 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg01569664 | chr13:109781669 | gene | -0.333596042670849 | 5.83769413887427e-07 | -0.5615256396949656 | 1.7981795555504443e-09 | PAAD |
| cg12085119 | chr13:109779344 | gene | -0.288196190398417 | 4.75150435081862e-05 | -0.4793327618583884 | 5.933486489864732e-07 | PAAD |
| cg20445402 | chr13:109779873 | gene | -0.470330372596656 | 1.17886274996971e-32 | -0.7296422407118756 | 1.6131660689550902e-34 | KIRP |
| cg25924746 | chr13:109780588 | gene | -0.275993907045403 | 1.13622224077387e-18 | -0.5918741396736822 | 2.1865111953316667e-20 | KIRP |
| cg20445402 | chr13:109779873 | gene | -0.255209984176809 | 6.00876834316976e-09 | -0.46314446423442046 | 8.927611437737463e-13 | LUAD |
| cg21266798 | chr13:109781289 | gene | -0.459205639333708 | 4.5064781286307e-22 | -0.631939579356626 | 6.288481266440425e-26 | STAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10488031 | chr13:109785214 | gene,exon,CDS,promoter | -0.453634638511449 | 5.11850126798427e-12 | -0.648326581493663 | 2.0732234270025514e-15 | STAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of IRS2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000185950 | IRS2 | C0002152 | Alloxan Diabetes | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0020456 | Hyperglycemia | 2 | CTD_human |
| ENSG00000185950 | IRS2 | C0021655 | Insulin Resistance | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0025149 | Medulloblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0038433 | Streptozotocin Diabetes | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0205833 | Medullomyoblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0278510 | Childhood Medulloblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0278876 | Adult Medulloblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0751291 | Desmoplastic Medulloblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C0920563 | Insulin Sensitivity | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C1275668 | Melanotic medulloblastoma | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| ENSG00000185950 | IRS2 | C1855520 | Hyperglycemia, Postprandial | 2 | CTD_human |
| ENSG00000185950 | IRS2 | C2239176 | Liver carcinoma | 1 | CTD_human |
